In this large, randomized control trial, over 1,000 patients were treated with sublingual ketamine. In this study over 50% of patients reduced depression and/or anxiety symptoms by >50% following just 3 ketamine sessions. Benefits increased further with 6 sessions.
https://www.frontiersin.org/journals/psychiatry/articles/10.3389/fpsyt.2022.992624/pdf
Hassan, K., Struthers, W. M., Sankarabhotla, A., & Davis, P. (2022). Safety, effectiveness, and tolerability of sublingual ketamine in depression and anxiety: A retrospective study of off-label, at-home use. Frontiers in Psychiatry, 13, Article 992624. https://doi.org/10.3389/fpsyt.2022.992624
This randomized control trial highlights rapid reduction in PTSD symptoms following Ketamine Treatment.
https://pubmed.ncbi.nlm.nih.gov/24740528/
Feder, A., Parides, M. K., Murrough, J. W., Perez, A. M., Morgan, J. E., Saxena, S., ... & Charney, D. S. (2014). Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial. JAMA Psychiatry, 71(6), 681-688.
Randomized Controlled Crossover Trial of Ketamine in Obsessive-Compulsive Disorder: Proof-of-Concept
Rodriguez, C. I., Kegeles, L. S., Levinson, A., Feng, T., Marcus, S. M., Vermes, D., ... & Simpson, H. B. (2013). Randomized controlled crossover trial of ketamine in obsessive-compulsive disorder: proof-of-concept. Neuropsychopharmacology, 38(12), 2475-2483.
https://pubmed.ncbi.nlm.nih.gov/22297150/
Zarate, C. A., Brutsche, N. E., Ibrahim, L., Franco-Chaves, J., Diazgranados, N., Cravchik, A., ... & Manji, H. K. (2012). Replication of ketamine’s antidepressant efficacy in bipolar depression: a randomized controlled add-on trial. Biological Psychiatry, 71(11), 939-946.
We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.